Legal Representation
Attorney
Scott D. Woldow
USPTO Deadlines
Next Deadline
609 days remaining
Section 71 Declaration Due (Principal Register 66a) (Based on registration date 20210831)
Due Date
August 31, 2027
Grace Period Ends
February 29, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 4, 2022 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
| Feb 27, 2022 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
| Feb 7, 2022 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
| Feb 7, 2022 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
| Nov 30, 2021 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
| Aug 31, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 15, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 15, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 26, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 12, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 11, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 11, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 11, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Dec 20, 2020 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
| Dec 3, 2020 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
| Dec 3, 2020 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
| Nov 17, 2020 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
| Nov 16, 2020 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 11, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 2, 2020 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Sep 28, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 24, 2020 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005